EndoBiologics International Corp., VaxGen deal

VXGN ended its 2005 deal to develop a vaccine against meningitis B with EndoBiologics (see BioCentury, May 9, 2005). VXGN had funded the first 12 months of preclinical proof-of-concept studies. ...